Combination treatment for vivax malaria
Part of Infections clinical trials.
This study tests a new combination of two medicines, SJ733 and tafenoquine, to see if it can safely and quickly cure vivax malaria. Vivax malaria can come back, so this treatment aims to prevent that relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh between 45 and 90 kg (about 100 to 200 pounds)
- Have a confirmed vivax malaria infection with fever and a certain level of parasites in your blood
- Be willing to stay in the hospital for at least 72 hours and return for follow-up visits over about 6 months
- If you are a woman, you must not be pregnant or breastfeeding and must agree to use effective birth control during the study and for 75 days after
- If you are a man, you must agree to use contraception or abstain from sex during the study and for 75 days after
- Not have certain health conditions like severe malaria, liver or kidney problems, heart issues, or G6PD deficiency
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether giving malaria medicine to people in high-risk households (a “mass drug administration” campaign) can stop local relapses and eliminate vivax malaria. If you live close to a recent malaria case, you may be offered a preventive dose, based on age and medical safety checks.
This trial tests a shorter course of the drug primaquine to prevent relapse of vivax malaria, a recurring type of malaria. It may offer a faster recovery with fewer doses.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This study compares two medicines (tafenoquine and primaquine) taken with chloroquine to treat P. vivax malaria. It aims to see which is safer and works better in Indian participants aged 2 to 64.
This study gives healthy adults who have never had malaria a controlled infection with the parasite that causes malaria, to see if it is safe and if mosquitoes can pick up the parasite from them. It may help develop new ways to prevent malaria.
This trial tests whether using a blood test to find and treat people infected with a type of malaria called Plasmodium vivax can reduce the spread of the disease. It may help you and your community stay healthier.
Hear when a new Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.